1. In Vivo
  2. >>Business Strategy

In Cardiovascular Devices, Who's Next?

Whereas much of the activity in cardiovascular M&A in the past seems to have come from a euphoric sense of the promise of cardiovascular medicine, the more recent moves have an air of frustrated hopes. The two large deals announced most recently, Boston Scientific Corp.'s acquisition of Pfizer Inc.'s Schneider angioplasty business and Medtronic Inc.'s purchase of external defibrillator company Physio-Control International corp. seem to have been driven by sellers looking for exit strategies as much as buyers looking for new opportunities.

For all of the frenetic acquisition and divestiture that has characterized the cardiovascular industry over the past several years, nothing seems to have matched the last two months. Certainly tremendous opportunities exist to encourage future dealing. But whereas much of the activity in cardiovascular in the past seems to have come from a euphoric sense of the promise of cardiovascular medicine, the more recent moves have an air of frustrated hopes.

In May, Heartport Inc. , once the darling of the minimally-invasive cardiac surgery market, announced a new CEO (Frank...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.